Search Results
12 Results Found for “endocarditis, ”
Native valve infective endocarditis (IE) is rare, with an incidence of 3–7 cases per 100,000 person-years.1,2 Cardiac structural complications from local infection extension include valvular destruction, peri-annular abscess and fistula formation. Left ventricular pseudoaneurysm (LVP) from IE is exceedingly rare, occurring in &...
The Evolut Low Risk trial (Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement; ClinicalTrials.gov identifier: NCT02701283) provides reassuring evidence that transcatheter aortic valve replacement (TAVR) ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1 If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along ...
The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common ...
Tricuspid regurgitation (TR) is a complex disease with several independent causes. Consequently, outcomes and response to therapy vary widely. Severe or progressive TR often results in gradual right ventricular (RV) failure and is associated with poor long-term outcomes.1 Most cases ...
Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk ...
...
Presentation A 73-year-old female with a history of recent bio-prosthetic aortic valve replacement, stroke, hypertension, breast cancer status post-lumpectomy and radiotherapy, and hyperlipidemia was admitted with shortness of breath and tachycardia. Her blood pressure (BP) was 147/65 and her pulse was 105/...
The use of electronic devices has increased during the past years; approximately 3.25 million pacemakers (PMs) and 180,000 implantable cardiac defibrillators (ICDs) have been implanted worldwide.1 The PM implant rates range from 200 implants per million in the UK, and 420 per million in ...
The subcutaneous implantable cardioverter-defibrillator (S-ICD) is a disruptive technological change in our approach to ICD implantation avoiding the Achilles’ heel of the transvenous lead impantation in patients without pacing indications. The evidence base has been significantly expanded over the past 12 ...
Introduction: The Micra TPS, a leadless single-chamber ventricular pacemaker, is increasingly preferred over the transvenous system. Its significantly smaller profile and fewer reported adverse effects, without compromising the pacing efficacy, makes it an innovative pacing device. We report the first ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
